Source comparison
Tesamorelin for NASH Support: Dosage, Peptide, and Combination Research Comparison
Tesamorelin 2mg daily GHRH analogue stimulating pulsatile GH release, preferentially mobilizing VAT and reducing hepatic lipid influx 28–37% at 26 weeks (1H-MRS data) Biomarker trends positive; histological data limited to 52 weeks (early improvement) VAT redu
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- GHRH analogue stimulating pulsatile GH release, preferentially mobilizing VAT and reducing hepatic lipid influx
- 28–37% at 26 weeks (1H-MRS data)
- Biomarker trends positive; histological data limited to 52 weeks (early improvement)
- VAT reduction 15–18%; neutral to improved HOMA-IR; HbA1c reduction 0.3%
- Best suited for NASH driven by central obesity and VAT excess; mechanism is upstream metabolic correction rather than direct hepatic action
- Semaglutide 2.4mg weekly
- GLP-1 receptor agonist reducing appetite, slowing gastric emptying, and improving insulin sensitivity
- 30–50% at 72 weeks (NASH trial data)
- NASH resolution 59% vs 17% placebo; fibrosis improvement in subset
- Mean body weight reduction 15–20%; significant HbA1c reduction
- Stronger direct hepatic anti-inflammatory effects; however, benefit is confounded by caloric restriction and weight loss
- Pioglitazone 30–45mg daily
- PPAR-gamma agonist improving insulin sensitivity and reducing hepatic inflammation
- 20–30% at 18 months
- Fibrosis improvement in 30–40% of responders (histology-confirmed)
- Weight gain 2–5kg common; fluid retention; improved insulin sensitivity
- Established NASH therapeutic with fibrosis data; side effect profile (weight gain, CHF risk) limits use in obese populations
- Tesamorelin + Ipamorelin
- Dual GHRH/GHRP pathway stimulation amplifying GH pulse magnitude and frequency
- Hypothesized additive effect (no published NASH trial data)
- Unknown; investigational only
- Enhanced VAT mobilization; greater IGF-1 elevation; potential for synergistic insulin sensitivity improvement
- Combination peptide stacks like Tesamorelin Ipamorelin Growth Hormone Stack are used in body composition research; NASH-specific data absent
- Vitamin E 800 IU daily
- Antioxidant reducing hepatic oxidative stress and lipid peroxidation
- 10–15% (modest)
- Improved steatosis and inflammation; no fibrosis benefit
- No significant metabolic effects; neutral on weight and glucose
- Safe, inexpensive, weak efficacy as monotherapy; often used adjunctively
- The comparison underscores tesamorelin's unique position: it's the only intervention in this table that achieves liver fat reduction primarily through VAT mobilization rather than caloric restriction, direct insulin sensitization, or antioxidant activity. For research models investigating the VAT-liver axis specifically, this mechanistic clarity is a major advantage.